UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000016662 |
|---|---|
| Receipt number | R000019339 |
| Scientific Title | Prognostic value of tubulointerstitial lesions, urinary N-acetyl-B-D-glucosaminidase, and urinary B2-microgrobulin in patients with type 2 diabetes and biopsy-proven diabetic nephropathy. |
| Date of disclosure of the study information | 2015/02/27 |
| Last modified on | 2015/08/31 09:09:25 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Prognostic value of tubulointerstitial lesions, urinary N-acetyl-B-D-glucosaminidase, and urinary B2-microgrobulin in patients with type 2 diabetes and biopsy-proven diabetic nephropathy.
Acronym
Tubulointerstitial lesions and urinary biomarkers
Scientific Title
Prognostic value of tubulointerstitial lesions, urinary N-acetyl-B-D-glucosaminidase, and urinary B2-microgrobulin in patients with type 2 diabetes and biopsy-proven diabetic nephropathy.
Scientific Title:Acronym
Tubulointerstitial lesions and urinary biomarkers
Region
| Japan |
Condition
Condition
Diabetic nephropathy
Classification by specialty
| Nephrology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To investigate the relationships of the extent of interstitial fibrosis and tubular atrophy with urinary NAG and urinary B2-MG, and to compared the value of these markers for predicting the renal prognosis in patients with type 2 diabetes and biopsy-proven DN.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
A decline of eGFR by at least 50% from baseline or commencement of dialysis due to end-stage renal disease
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 18 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Patients with type2 diabetes who underwent renal biopsy at our hospital from March 1985 to June 2011 and were confirmed to have diabetic nephropathy according to Tervaert's classification(J Am Soc Nephrol. 2010;21(4):556-63)
Key exclusion criteria
Patients in whom urinary NAG and B2-MG were not examined at the time of renal biopsy
Patients whose baseline eGFR was <10 mL/min/1.73m2
Target sample size
120
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Yoshifumi Ubara |
Organization
Toranomon Hospital Kajigaya
Division name
Nephrology Center
Zip code
Address
1-3-1, Kajigaya, Takatu-ku, Kawasaki-shi, Kanagawa-ken, 213-0015, Japan
TEL
044-877-5111
ubara@toranomon.gr.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Koki Mise |
Organization
Toranomon Hospital Kajigaya
Division name
Nephrology Center
Zip code
Address
1-3-1, Kajigaya, Takatu-ku, Kawasaki-shi, Kanagawa-ken, 213-0015, Japan
TEL
044-877-5111
Homepage URL
kokims-frz@umin.ac.jp
Sponsor or person
Institute
Toranomon Hospital
Institute
Department
Personal name
Funding Source
Organization
Okinaka Memorial Institute for Medical Research
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
虎の門病院分院(神奈川県)、虎の門病院(東京)
Other administrative information
Date of disclosure of the study information
| 2015 | Year | 02 | Month | 27 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2015 | Year | 01 | Month | 15 | Day |
Date of IRB
Anticipated trial start date
| 2015 | Year | 01 | Month | 17 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Cox proportional hazards regression analysis was used to calculate the hazard ratio and 95% confidence interval for death-censored endpoint, with each regression analysis examining two levels of multivariate adjustment.
Management information
Registered date
| 2015 | Year | 02 | Month | 27 | Day |
Last modified on
| 2015 | Year | 08 | Month | 31 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019339
